iBET - Instituto de Biologia Experimental e Tecnológica

iBET has coordinated over 30 international projects and participated in more than 100 EU-funded projects, securing collaborations with prominent international pharmaceutical companies. With a staff of over 250 individuals, including approximately 110 with PhD degrees, iBET is well-equipped to contribute significantly to the biotechnology industry. Founded in 1989, iBET has positioned itself as a noteworthy player in the field of biotechnology, with a demonstrated track record of international impact and collaborations with leading industry names such as Bayer, Novartis, Merck, Abbvie, Sanofi, Apceth, AstraZeneca, Glaxo-Smith-Kline, and Merck & Co. iBET continues to be a pioneering force in providing biotech solutions globally, with a focus on fostering innovation and advancing biotechnological research and development.